{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:17:24Z","timestamp":1790273844070,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymthe.2025.05.027","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:39:15Z","timestamp":1748374755000},"page":"4338-4359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disease-modifying, multidimensional efficacy of putaminal CaV1.3-shRNA gene therapy in aged parkinsonism male and female macaques"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-2310","authenticated-orcid":false,"given":"Kathy","family":"Steece-Collier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly J.","family":"Vander Werp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Stancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette M.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Kordower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.05.027_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jval.2013.08.1820","article-title":"Burden of L-Dopa-Induced Dyskinesia in Parkinson\u2019s Disease Patients (PD-LID) in France \u2013 the Lidia Study Economic Analysis (Levodopa Induced Dyskinesia Impact Evaluation)","volume":"16","author":"Kryskowiak","year":"2013","journal-title":"Value in Health"},{"key":"10.1016\/j.ymthe.2025.05.027_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fneur.2013.00090","article-title":"Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD","volume":"4","author":"de la Fuente-Fernandez","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","article-title":"Time Trends in the Incidence of Parkinson Disease","volume":"73","author":"Savica","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The Emerging Evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.26122","article-title":"Levodopa: 50 years of a revolutionary drug for Parkinson disease","volume":"30","author":"Fahn","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib6","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/mds.22759","article-title":"Levodopa response in early Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s13311-020-00965-9","article-title":"BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease","volume":"17","author":"Fischer","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.05.027_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.26050","article-title":"Improving L-dopa therapy: the development of enzyme inhibitors","volume":"30","author":"Gershanik","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1877718X241310727","article-title":"Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study","volume":"15","author":"Isaacson","year":"2025","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib10","article-title":"Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations","author":"Koeglsperger","year":"2025","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ymthe.2025.05.027_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mds.26078","article-title":"Novel formulations and modes of delivery of levodopa","volume":"30","author":"Poewe","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/164_2022_629","article-title":"The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease","volume":"279","author":"Caulfield","year":"2023","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.05.027_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuroscience.2011.08.045","article-title":"The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease","volume":"198","author":"Surmeier","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2025.05.027_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.expneurol.2017.08.001","article-title":"Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease","volume":"298","author":"Surmeier","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00424-020-02418-w","article-title":"De novo CACNA1D Ca(2+) channelopathies: clinical phenotypes and molecular mechanism","volume":"472","author":"Ortner","year":"2020","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ymthe.2025.05.027_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030933","article-title":"Likely Pathogenic Variants of Ca(v)1.3 and Na(v)1.1 Encoding Genes in Amyotrophic Lateral Sclerosis Could Elucidate the Dysregulated Pain Pathways","volume":"11","author":"Nagy","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2025.05.027_bib19","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1212\/NXG.0000000000000072","article-title":"DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient","volume":"2","author":"Wang","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.ymthe.2025.05.027_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","article-title":"The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease","volume":"43","author":"Ilijic","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib21","doi-asserted-by":"crossref","first-page":"47284","DOI":"10.18632\/oncotarget.17618","article-title":"Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.05.027_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00001756-199503000-00009","article-title":"Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice","volume":"6","author":"Kupsch","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.ymthe.2025.05.027_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/acn3.412","article-title":"A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)","volume":"4","author":"Biglan","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial","volume":"172","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2025.05.027_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mds.28850","article-title":"Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease","volume":"37","author":"Surmeier","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M20-1023","article-title":"A Clinical Trial of Isradipine: What Went Wrong?","volume":"172","author":"Maiti","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2025.05.027_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/acn3.51300","article-title":"Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease","volume":"8","author":"Venuto","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopsych.2008.09.008","article-title":"Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"65","author":"Schuster","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.05.027_bib29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1460-9568.2010.07077.x","article-title":"Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats","volume":"31","author":"Soderstrom","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.27695","article-title":"Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia","volume":"34","author":"Steece-Collier","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn1632","article-title":"Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models","volume":"9","author":"Day","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuro.2005.02.002","article-title":"Pathological synaptic plasticity in the striatum: implications for Parkinson's disease","volume":"26","author":"Picconi","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2025.05.027_bib35","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","article-title":"Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses","volume":"33","author":"Zhang","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106111","article-title":"Downregulation of striatal Ca(V)1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age","volume":"181","author":"Caulfield","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.20411\/pai.v2i3.186","article-title":"The Critical Role of Nonhuman Primates in Medical Research","volume":"2","author":"Friedman","year":"2017","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.ymthe.2025.05.027_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jnnp-2022-330790","article-title":"Longitudinal decline in striatal dopamine transporter binding in Parkinson's disease: associations with apathy and anhedonia","volume":"94","author":"Costello","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2025.05.027_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00415-008-0636-x","article-title":"Subthalamic nucleus stimulation and levodopa-resistant postural instability in Parkinson's disease","volume":"255","author":"Visser","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/mds.26269","article-title":"Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease","volume":"30","author":"Curtze","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.02.021","article-title":"Do patients with late-stage Parkinson's disease still respond to levodopa?","volume":"26","author":"Fabbri","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib42","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.3233\/JPD-202096","article-title":"Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease","volume":"10","author":"Fabbri","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0306-4522(99)00437-6","article-title":"Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment","volume":"95","author":"Elsworth","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2025.05.027_bib44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3727\/000000006783982025","article-title":"Neural repair strategies for Parkinson's disease: insights from primate models","volume":"15","author":"Soderstrom","year":"2006","journal-title":"Cell Transpl."},{"key":"10.1016\/j.ymthe.2025.05.027_bib45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.05.027_bib46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2012.04.025","article-title":"Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys","volume":"236","author":"Brown","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib47","article-title":"Treatment of advanced Parkinson's disease","volume":"2010","author":"Varanese","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/mdc3.13687","article-title":"Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging","volume":"10","author":"Heng","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.ymthe.2025.05.027_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archneur.1994.00540150027011","article-title":"Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data","volume":"51","author":"Sawle","year":"1994","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fnana.2015.00005","article-title":"Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state","volume":"9","author":"Galvan","year":"2015","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2025.05.027_bib51","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s12035-014-8688-7","article-title":"Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys","volume":"50","author":"Azkona","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.brainresrev.2004.09.008","article-title":"Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels","volume":"48","author":"Romanelli","year":"2005","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.ymthe.2025.05.027_bib54","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009621","article-title":"Functional neuroanatomy of the basal ganglia","volume":"2","author":"Lanciego","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2025.05.027_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5114\/bta.2021.111111","article-title":"Retrograde capabilities of adeno-associated virus vectors in the central nervous system","volume":"102","author":"Surdyka","year":"2021","journal-title":"BioTechnologia (Pozn)"},{"key":"10.1016\/j.ymthe.2025.05.027_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2018.01.002","article-title":"Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson's progression: Evidence from clinical studies and neurotoxin models","volume":"165\u2013167","author":"Johnson","year":"2018","journal-title":"Prog. Neurobiol."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2025.05.027_bib57","first-page":"S63","article-title":"A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease","volume":"25","author":"Chan","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.636103","article-title":"Voltage-Gated Ca(2+) Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?","volume":"13","author":"Ortner","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/cne.25570","article-title":"Cholinergic and Nadph-delta neurons in the pedunculopontine and laterodorsal tegmental nuclei of human and nonhuman primates","volume":"532","author":"Coulombe","year":"2024","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib60","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1523\/JNEUROSCI.0529-23.2023","article-title":"Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Nonhuman Primate Model of Parkinson's Disease","volume":"43","author":"Rahamim","year":"2023","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2024.1355940","article-title":"Development and characterization of a non-human primate model of disseminated synucleinopathy","volume":"18","author":"Rico","year":"2024","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2025.05.027_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120120","article-title":"A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures","volume":"10","author":"Grabinski","year":"2015","journal-title":"PloS one"},{"key":"10.1016\/j.ymthe.2025.05.027_bib63","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1523\/JNEUROSCI.19-09-03345.1999","article-title":"Tonic dopamine inhibition of L-type Ca2+ channel activity reduces alpha1D Ca2+ channel gene expression","volume":"19","author":"Fass","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/apha.12883","article-title":"Transcriptional regulation of voltage-gated Ca(2+) channels","volume":"222","author":"Gonzalez-Ramirez","year":"2018","journal-title":"Acta Physiol. (Oxf)"},{"key":"10.1016\/j.ymthe.2025.05.027_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12031-009-9299-z","article-title":"Role of AP-2alpha transcription factor in the regulation of synapsin II gene expression by dopamine D1 and D2 receptors","volume":"41","author":"Skoblenick","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2017.06.011","article-title":"Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS","volume":"8","author":"Kanaan","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.027_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102332","article-title":"Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS","volume":"35","author":"Sandoval","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.027_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114694","article-title":"Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets","volume":"374","author":"Daadi","year":"2024","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib69","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41531-022-00440-6","article-title":"Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson's disease in animal models","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","article-title":"Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys","volume":"27","author":"Tao","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.05.027_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103827","article-title":"Induced Cognitive Impairments Reversed by Grafts of Neural Precursors: A Longitudinal Study in a Macaque Model of Parkinson's Disease","volume":"9","author":"Wianny","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-1-4939-3271-9_32","article-title":"AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned?","volume":"1382","author":"Kordower","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.593572","article-title":"The Future of GDNF in Parkinson's Disease","volume":"12","author":"Manfredsson","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib74","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.29518","article-title":"Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery","volume":"38","author":"Chu","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib75","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00702-016-1596-4","article-title":"Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects","volume":"123","author":"Nagatsu","year":"2016","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ymthe.2025.05.027_bib76","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.05.027_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104525","article-title":"Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal alpha-synuclein preformed fibrils","volume":"130","author":"Patterson","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib78","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009290","article-title":"Physiological phenotype and vulnerability in Parkinson's disease","volume":"2","author":"Surmeier","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2025.05.027_bib79","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease","volume":"288","author":"Surmeier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.05.027_bib80","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","article-title":"Living on the edge with too many mouths to feed: why dopamine neurons die","volume":"27","author":"Bolam","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib81","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2016.08.168","article-title":"Calcium and Parkinson's disease","volume":"483","author":"Surmeier","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.05.027_bib82","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","article-title":"Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics","volume":"21","author":"Kang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ymthe.2025.05.027_bib83","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","article-title":"Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)","volume":"28","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib84","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/nan.12678","article-title":"L-DOPA regulates alpha-synuclein accumulation in experimental parkinsonism","volume":"47","author":"Deffains","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158586","article-title":"Increased Expression of Alpha-Beta-and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease","volume":"23","author":"Duperrier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.05.027_bib86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0963689719835794","article-title":"alpha-Synuclein Expression Is Preserved in Substantia Nigra GABAergic Fibers of Young and Aged Neurotoxin-Treated Rhesus Monkeys","volume":"28","author":"Vermilyea","year":"2019","journal-title":"Cell Transpl."},{"key":"10.1016\/j.ymthe.2025.05.027_bib87","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/brain\/awz296","article-title":"Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes","volume":"142","author":"Chu","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.05.027_bib88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00702-017-1720-0","article-title":"alpha-Synuclein nonhuman primate models of Parkinson's disease","volume":"125","author":"Marmion","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ymthe.2025.05.027_bib89","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s13311-017-0532-0","article-title":"From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms","volume":"14","author":"Kabir","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.05.027_bib90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10059-011-0075-x","article-title":"Effects of amyloid-beta peptides on voltage-gated L-type Ca(V)1.2 and Ca(V)1.3 Ca(2+) channels","volume":"32","author":"Kim","year":"2011","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ymthe.2025.05.027_bib91","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mdc3.12476","article-title":"Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration","volume":"4","author":"Skorvanek","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.ymthe.2025.05.027_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113534","article-title":"Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia","volume":"336","author":"Lanza","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4939-9065-8_6","article-title":"Multimodal Production of Adeno-Associated Virus","volume":"1937","author":"Sandoval","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.05.027_bib94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/hgtb.2015.117","article-title":"Continuous Collection of Adeno-Associated Virus from Producer Cell Medium Significantly Increases Total Viral Yield","volume":"27","author":"Benskey","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2025.05.027_bib95","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.3233\/JPD-212679","article-title":"Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies","volume":"11","author":"Sandoval","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib96","doi-asserted-by":"crossref","DOI":"10.3791\/62970","article-title":"Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease","author":"Caulfield","year":"2021","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymthe.2025.05.027_bib97","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3233\/JPD-2011-11068","article-title":"Putaminal upregulation of FosB\/DeltaFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia","volume":"1","author":"Lindgren","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.027_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.82","article-title":"Impact of age and vector construct on striatal and nigral transgene expression","volume":"3","author":"Polinski","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.05.027_bib99","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2025.05.027_bib100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2014.02.027","article-title":"Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease","volume":"566","author":"Ko","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2025.05.027_bib101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2818.1987.tb02837.x","article-title":"The efficiency of systematic sampling in stereology and its prediction","volume":"147","author":"Gundersen","year":"1987","journal-title":"J. Microsc."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:26:46Z","timestamp":1782505606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625003971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525001625003971"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying, multidimensional efficacy of putaminal CaV1.3-shRNA gene therapy in aged parkinsonism male and female macaques","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}